Sarepta Therapeutics,, Inc. Common Stock (SRPT)

Price$15.75

Value ScoreB

Growth ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-34.12%

Price vs S&P 500 (4W)-21.06%

VGM Score49.17

Market Capitalization$1.66B

P/E Ratio (Annual)7.77x

All Metrics

Book Value / Share (Quarterly)$14.26

P/TBV (Annual)2.03x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)33.07%

Cash Flow / Share (Quarterly)$1.03

Price vs S&P 500 (YTD)-34.97%

Gross Margin (TTM)70.45%

Net Profit Margin (TTM)2.98%

EPS (TTM)$0.07

10-Day Avg Trading Volume3.02M

EPS Excl Extra (TTM)$0.07

Revenue Growth (5Y)32.41%

EPS (Annual)$-7.13

ROI (Annual)-36.22%

Gross Margin (Annual)69.33%

Net Profit Margin (5Y Avg)-39.65%

Cash / Share (Quarterly)$6.19

P/E Basic Excl Extra (TTM)25.56x

Revenue Growth QoQ (YoY)-1.89%

P/E Normalized (Annual)7.77x

ROA (Last FY)-21.30%

Revenue Growth TTM (YoY)-2.20%

EBITD / Share (TTM)$-0.20

ROE (5Y Avg)-67.48%

Operating Margin (TTM)-1.10%

Cash Flow / Share (Annual)$-3.00

P/B Ratio1.10x

P/B Ratio (Quarterly)1.52x

Net Income / Employee (Annual)$-854,400

EV / Revenue (TTM)0.93x

Net Interest Coverage (TTM)-29.15x

ROA (TTM)1.90%

EV / EBITDA (TTM)1323.29x

EPS Incl Extra (Annual)$-7.13

Current Ratio (Annual)2.32x

Quick Ratio (Quarterly)2.56x

3-Month Avg Trading Volume2.88M

52-Week Price Return-59.83%

P/E Incl Extra (TTM)25.56x

Revenue / Employee (TTM)$2,615,800

Tangible BV / Share (Quarterly)$13.96

P/S Ratio (Annual)0.76x

Asset Turnover (Annual)0.66x

52-Week High$43.92

Operating Margin (5Y Avg)-37.86%

EPS Excl Extra (Annual)$-7.13

CapEx CAGR (5Y)5.09%

Tangible BV CAGR (5Y)8.24%

26-Week Price Return-26.19%

Quick Ratio (Annual)1.44x

13-Week Price Return-2.96%

Total Debt / Equity (Annual)0.73x

Current Ratio (Quarterly)4.63x

Enterprise Value$2.04B

Revenue / Share Growth (5Y)25.96%

Asset Turnover (TTM)0.64x

Book Value / Share Growth (5Y)2.52%

Revenue / Employee (Annual)$2,632,600

Inventory Turnover (Annual)0.81x

Pretax Margin (Annual)-31.94%

Cash / Share (Annual)$8.95

3-Month Return Std Dev89.18%

Gross Margin (5Y Avg)82.32%

Net Income / Employee (TTM)$77,900

ROE (Last FY)-62.55%

Net Interest Coverage (Annual)2.64x

EPS Basic Excl Extra (Annual)$-7.13

P/FCF (TTM)4.66x

Receivables Turnover (TTM)4.14x

EV / Free Cash Flow (TTM)18.82x

Total Debt / Equity (Quarterly)0.56x

EPS Incl Extra (TTM)$0.07

Receivables Turnover (Annual)4.40x

ROI (TTM)2.84%

P/S Ratio (TTM)0.76x

Pretax Margin (5Y Avg)-38.74%

Revenue / Share (Annual)$21.96

Tangible BV / Share (Annual)$10.59

Forward P/E7.11x

Price vs S&P 500 (52W)-84.20%

P/E Ratio (TTM)25.56x

Year-to-Date Return-26.81%

5-Day Price Return-10.56%

EPS Normalized (Annual)$-7.13

ROA (5Y Avg)-13.51%

Net Profit Margin (Annual)-32.45%

Month-to-Date Return-11.86%

Cash Flow / Share (TTM)$-7.32

EBITD / Share (Annual)$-6.79

Operating Margin (Annual)-31.07%

LT Debt / Equity (Annual)0.73x

P/CF (TTM)9.49x

ROI (5Y Avg)-22.02%

P/E Excl Extra (TTM)25.56x

LT Debt / Equity (Quarterly)0.56x

EPS Basic Excl Extra (TTM)$0.07

P/TBV (Quarterly)1.55x

P/B Ratio (Annual)1.98x

Inventory Turnover (TTM)0.66x

Pretax Margin (TTM)1.12%

Book Value / Share (Annual)$10.87

Price vs S&P 500 (13W)-11.21%

Beta0.24x

P/FCF (Annual)76.28x

Revenue / Share (TTM)$17.92

ROE (TTM)4.89%

52-Week Low$10.42

vGradeB

gGradeC

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 262.88est. 1.01

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.36

3.42

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
SRPTSarepta Therapeutics,, Inc. Common Stock	B	C	D	$15.75
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Sarepta Therapeutics is a commercial-stage biopharmaceutical company specializing in RNA-targeted and gene therapies for rare neuromuscular disorders. The company has four FDA-approved treatments for Duchenne muscular dystrophy and maintains a pipeline of additional candidates for neuromuscular and other rare diseases. Its integrated business model encompasses discovery through patient delivery of genetic medicines for underserved patient populations.